Recent News

• 12.12.2025 - Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
• 11.26.2025 - Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
• 11.10.2025 - Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.07.2025 - Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
• 11.05.2025 - Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Recent Filings

• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 144 Report of proposed sale of securities